Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

W. C. Zamboni, S. Strychor, L. Maruca, S. Ramalingam, B. A. Zamboni, H. Wu, D. M. Friedland, R. P. Edwards, R. G. Stoller, Chandra Belani, R. K. Ramanathan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients 60 years of age have a 2.7-fold higher exposure of S-CKD602 as compared with patients 60 years of age (P = 0.02). Patients with a lean body composition have a higher plasma exposure of S-CKD602 (P = 0.02). Patients who have received prior therapy with pegylated liposomal doxorubicin (PLD) have a 2.2-fold higher exposure of S-CKD602 as compared with patients who have not received PLD (P = 0.045). Prolonged exposure of the encapsulated drug in plasma over 1-2 weeks provides significant pharmacologic advantages. The high interpatient variability in the pharmacokinetic disposition of S-CKD602 was associated with age, body composition, saturable clearance, and prior PLD therapy.

Original languageEnglish (US)
Pages (from-to)519-526
Number of pages8
JournalClinical pharmacology and therapeutics
Volume86
Issue number5
DOIs
StatePublished - Nov 1 2009

Fingerprint

Pharmacokinetics
Neoplasms
Body Composition
belotecan
Therapeutics
Pharmaceutical Preparations
liposomal doxorubicin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Zamboni, W. C., Strychor, S., Maruca, L., Ramalingam, S., Zamboni, B. A., Wu, H., ... Ramanathan, R. K. (2009). Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clinical pharmacology and therapeutics, 86(5), 519-526. https://doi.org/10.1038/clpt.2009.141
Zamboni, W. C. ; Strychor, S. ; Maruca, L. ; Ramalingam, S. ; Zamboni, B. A. ; Wu, H. ; Friedland, D. M. ; Edwards, R. P. ; Stoller, R. G. ; Belani, Chandra ; Ramanathan, R. K. / Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. In: Clinical pharmacology and therapeutics. 2009 ; Vol. 86, No. 5. pp. 519-526.
@article{d23c7f87f6e44424bd9948c596091bb7,
title = "Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies",
abstract = "S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients 60 years of age have a 2.7-fold higher exposure of S-CKD602 as compared with patients 60 years of age (P = 0.02). Patients with a lean body composition have a higher plasma exposure of S-CKD602 (P = 0.02). Patients who have received prior therapy with pegylated liposomal doxorubicin (PLD) have a 2.2-fold higher exposure of S-CKD602 as compared with patients who have not received PLD (P = 0.045). Prolonged exposure of the encapsulated drug in plasma over 1-2 weeks provides significant pharmacologic advantages. The high interpatient variability in the pharmacokinetic disposition of S-CKD602 was associated with age, body composition, saturable clearance, and prior PLD therapy.",
author = "Zamboni, {W. C.} and S. Strychor and L. Maruca and S. Ramalingam and Zamboni, {B. A.} and H. Wu and Friedland, {D. M.} and Edwards, {R. P.} and Stoller, {R. G.} and Chandra Belani and Ramanathan, {R. K.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1038/clpt.2009.141",
language = "English (US)",
volume = "86",
pages = "519--526",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

Zamboni, WC, Strychor, S, Maruca, L, Ramalingam, S, Zamboni, BA, Wu, H, Friedland, DM, Edwards, RP, Stoller, RG, Belani, C & Ramanathan, RK 2009, 'Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies', Clinical pharmacology and therapeutics, vol. 86, no. 5, pp. 519-526. https://doi.org/10.1038/clpt.2009.141

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. / Zamboni, W. C.; Strychor, S.; Maruca, L.; Ramalingam, S.; Zamboni, B. A.; Wu, H.; Friedland, D. M.; Edwards, R. P.; Stoller, R. G.; Belani, Chandra; Ramanathan, R. K.

In: Clinical pharmacology and therapeutics, Vol. 86, No. 5, 01.11.2009, p. 519-526.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

AU - Zamboni, W. C.

AU - Strychor, S.

AU - Maruca, L.

AU - Ramalingam, S.

AU - Zamboni, B. A.

AU - Wu, H.

AU - Friedland, D. M.

AU - Edwards, R. P.

AU - Stoller, R. G.

AU - Belani, Chandra

AU - Ramanathan, R. K.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients 60 years of age have a 2.7-fold higher exposure of S-CKD602 as compared with patients 60 years of age (P = 0.02). Patients with a lean body composition have a higher plasma exposure of S-CKD602 (P = 0.02). Patients who have received prior therapy with pegylated liposomal doxorubicin (PLD) have a 2.2-fold higher exposure of S-CKD602 as compared with patients who have not received PLD (P = 0.045). Prolonged exposure of the encapsulated drug in plasma over 1-2 weeks provides significant pharmacologic advantages. The high interpatient variability in the pharmacokinetic disposition of S-CKD602 was associated with age, body composition, saturable clearance, and prior PLD therapy.

AB - S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients 60 years of age have a 2.7-fold higher exposure of S-CKD602 as compared with patients 60 years of age (P = 0.02). Patients with a lean body composition have a higher plasma exposure of S-CKD602 (P = 0.02). Patients who have received prior therapy with pegylated liposomal doxorubicin (PLD) have a 2.2-fold higher exposure of S-CKD602 as compared with patients who have not received PLD (P = 0.045). Prolonged exposure of the encapsulated drug in plasma over 1-2 weeks provides significant pharmacologic advantages. The high interpatient variability in the pharmacokinetic disposition of S-CKD602 was associated with age, body composition, saturable clearance, and prior PLD therapy.

UR - http://www.scopus.com/inward/record.url?scp=70350231916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350231916&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.141

DO - 10.1038/clpt.2009.141

M3 - Article

C2 - 19675541

AN - SCOPUS:70350231916

VL - 86

SP - 519

EP - 526

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -